VFY: US blood partnerships widen reach as FDA listing nears
VFY says US blood partnerships reach about 17% of civilian collection sites and a Charter Medical deal opens cell and gene therapy, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
VFY reports that its blood partnerships in the United States now span roughly 17% of civilian collection sites. TradingView's summary of the update, which it labels as AI-generated, put the number of civilian partners at three.
A Charter Medical agreement gives the company access to the cell and gene therapy market. Cash and term deposits at quarter-end totalled A$38.3m, although a second version of the same report gives the figure as $38.3m without specifying a currency.
Manufacturing, validation and FDA listing preparations are moving ahead, with the listing still targeted for the end of 1H FY2027.
why it matters
For investors, the update is mainly an operating milestone for a small listed company rather than a market-moving event. It signals wider commercial reach in the US and entry into a new therapy segment, while the FDA listing remains the next major checkpoint to watch.
tags
instruments
sources
- VFY: U.S. partnerships broaden the market reach as FDA listing and manufacturing preparations advance — TradingView, 27 October 2026 at 21:44 UTC
- VFY: U.S. partnerships expand reach as device manufacturing and FDA listing near — TradingView, 27 October 2026 at 21:43 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗